文献速递妇科肿瘤泌尿男性生殖肿瘤支持与姑息治疗

全球近距离放疗资源供需评估:基于人群的观察性研究

Assessing the global demand and supply of brachytherapy resources: a population-based observational study.
PubMed 文献 · Lancet Oncol · 2026-01-01

该研究基于GLOBOCAN 2022数据,评估185个国家六种癌症的近距离放疗需求与供给。全球近距离放疗可及性严重不均。

要点

  • 低收入国家患者平均出行距离551 km,远超高收入国家的68 km。

核心结论

  • 全球近距离放疗可及性严重不平等,充足覆盖主要限于高收入国家,低收入地区资源缺口最大且患者出行最远。

研究设计与样本

  • 基于人群的观察性研究,从GLOBOCAN 2022获取185个国家六种癌症发病率,从Directory of Radiotherapy Centres提取近距离放疗中心数据并辅以文献综述,按世界银行收入分组。

主要发现

  • 缺口最大地区为撒哈拉以南非洲、东亚和东南亚。

关键数值与推荐

  • 中心年容量定义为218例患者,基于高收入国家容量。
  • 利用Collaboration for Cancer Outcomes Research and Evaluation模型的近距离放疗利用率估算高收入国家需求,调整模型考虑中低收入国家晚期就诊。
  • 阴道癌近距离放疗利用率单独估算。
  • 欧几里得分析用于计算人口密度超过608人/km²地区到中心的平均人口加权距离。

临床怎么用

  • 应优先在低收入和中等收入国家投资建设近距离放疗中心,以缩小地理和经济可及性障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brachytherapy is a key component of cancer treatment, yet global access remains poorly characterised. We aimed to quantify worldwide demand and supply of brachytherapy resources and to identify inequities in access. METHODS: In this population-based observational study, cancer incidence for six cancers (prostate, vaginal, cervical, endometrial, and vulval cancers, and melanoma) in 185 countries was obtained from GLOBOCAN 2022. Data on brachytherapy centres was extracted from the Directory of Radiotherapy Centres (accessed May 7, 2024) and supplemented by a literature review when brachytherapy caseloads exceeded 500 patients per centre. Annual centre capacity was defined as 218 patients, based on HIC capacity. Countries were classified by World Bank income groups. Brachytherapy utilisation rates from the Collaboration for Cancer Outcomes Research and Evaluation model were applied to estimate demand in high-income countries (HICs). An adjusted model accounted for later-stage presentation in low-income countries (LICs) and middle-income countries (excluding prostate cancer since alternative treatments are available). Brachytherapy utilisation for vulval cancer was separately estimated. Euclidean analysis was used to calculate the average population-weighted travel distance to centres in areas with more than 608 people per km·. FINDINGS: 18 528 336 new cancer cases (excluding non-melanoma skin cancer) occurred in 185 countries in 2022, of which 708 948 were estimated to require brachytherapy, corresponding to a global brachytherapy utilisation rate of 3·8%. Cervical cancer accounted for the majority of brachytherapy indications (59·3%, n=420 090), followed by uterine (25·2%, n=178 584) and prostate cancer (11·5%, n=81 849), with smaller numbers for vaginal (2·0%, n=13 996), vulval (1·1%, n=7611), and ocular melanoma (1·0%, n=6817). Brachytherapy demand was met in most HICs (81·5%), some upper-middle-income countries (UMIC; 44·4%), few lower-middle-income countries (LMIC; 11·8%), and in no LICs. The regions with the biggest deficit were sub-Saharan Africa, eastern Asia, and south-eastern Asia. Utilisation rates were higher in LICs (10·4%) compared with LMICs (5·7%), UMIC (3·5%), and HICs (2·9%). Average population-weighted distance to the nearest centre was 68 km in HICs, 167 km in UMICs, 341 km in LMICs, and 551 km in LICs (p<0·0001). INTERPRETATION: Global access to brachytherapy remains profoundly unequal, with adequate coverage largely limited to HICs. Resource gaps are greatest in lower-income settings, where patients also travel farthest. Investment in new centres is urgently needed to reduce geographical and economic barriers to access. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hajeer A, Salem A, Akash M, et al. Assessing the global demand and supply of brachytherapy resources: a population-based observational study. Lancet Oncol. 2026. PMID: 41785895. doi:10.1016/S1470-2045(25)00718-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。